Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Pisa – page 33

582 clinical trials in Pisa, Italy across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Pisa at a glance
582
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

582 trials in Pisa

Open in trial search

Pancreatic carcinoma metastatic

Not recruiting

Study of RMC-6236 compared to standard therapy in previously treated metastatic pancreatic ductal adenocarcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Revolution Medicines Inc.

Diffuse large B-cell lymphoma

Not recruiting

Study on the Effectiveness and Safety of Ibrutinib with Rituximab-CHOP for Untreated Patients with Diffuse Large B-cell Lymphoma at High Risk

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:Fondazione Italiana Linfomi Ets

Follicular lymphoma

Not recruiting

Study Comparing Shortened vs Standard Chemotherapy with Rituximab for Initial Treatment of High Tumor Burden Follicular Lymphoma in Newly Diagnosed Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bendamustine
  • Sponsor:Fondazione Italiana Linfomi Ets

Chronic obstructive pulmonary disease

Not recruiting

Study of tozorakimab effectiveness and safety in former smokers with Chronic Obstructive Pulmonary Disease (COPD) who experience disease flare-ups

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol
  • Sponsor:AstraZeneca AB

Triple negative breast cancer

Not recruiting

Study on Avelumab for Patients with High-Risk Triple Negative Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Universita Degli Studi Di Padova

Cardiac amyloidosis

Not recruiting

Study on the Use of Flutemetamol (18F) for Diagnosing Cardiac Amyloidosis in Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Flutemetamol (18F)
  • Sponsor:Fondazione Toscana Gabriele Monasterio

Pulmonary arterial hypertension

Not recruiting

Study of Sotatercept for People with Pulmonary Arterial Hypertension

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Merck Sharp & Dohme LLC

Type 2 diabetes mellitus+2

Not recruiting

Study of NNC0519-0130 and semaglutide in people with chronic kidney disease who are overweight or obese, with or without type 2 diabetes

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Endocrine ophthalmopathy

Not recruiting

Study on Batoclimab for Treating Patients with Active Thyroid Eye Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Batoclimab
  • Sponsor:Immunovant Sciences GmbH

Hepatic cirrhosis

Not recruiting

Study of Resmetirom in Patients with Well-compensated Non-alcoholic Steatohepatitis (NASH) Cirrhosis to Evaluate Effects on Liver Health

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Resmetirom
  • Sponsor:Madrigal Pharmaceuticals Inc.

Colorectal cancer metastatic+1

Not recruiting

Study of Encorafenib, Cetuximab, and Pembrolizumab for Patients with Untreated BRAF V600E-Mutant Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Pfizer Inc.

Parkinson's disease

Not recruiting

Study on the Effects and Safety of Prasinezumab for Patients with Early Parkinson's Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Prasinezumab
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Pisa

What the registry says about research in the country

01 Cardiovascular & Metabolic Research

Investigating innovative treatments for cardiac conditions and metabolic disorders, with studies focusing on TTR amyloidosis cardiomyopathy and chronic kidney disease management.

  • Heart Disease Therapeutics
  • Kidney Disease Management
  • Hypertension Control

Current trials evaluate novel compounds for improving patient outcomes in cardiac conditions and renal disorders.

02 Oncology Studies

Comprehensive research into various cancer types, including colorectal cancer, gastric cancer, and lung cancer, testing targeted therapies and innovative treatment combinations.

  • Metastatic Cancer Treatment
  • Targeted Therapy Development
  • Immunotherapy Research

Advanced clinical trials exploring breakthrough treatments for multiple cancer types.

03 Autoimmune & Inflammatory Conditions

Studies focusing on chronic inflammatory conditions including Sjögren's Syndrome, psoriatic arthritis, and hidradenitis suppurativa.

  • Inflammatory Disease Management
  • Autoimmune Treatment Innovation
  • Novel Therapeutic Approaches

Evaluating new therapeutic options for improving quality of life in patients with chronic inflammatory conditions.

04 Respiratory & Infectious Diseases

Research into respiratory conditions and infectious diseases, including studies on chronic rhinosinusitis and respiratory syncytial virus infections.

  • Respiratory Disease Treatment
  • Infection Management
  • Vaccine Development

Investigating new approaches to treat and prevent respiratory infections and related conditions.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.